Last reviewed · How we verify

NCT04697706

Effect of a High Citrate Beverage on Urine Chemistry in Urinary Stone Disease

Completed EARLY_PHASE1 Last updated 6 January 2021
What this trial tests

EARLY_PHASE1 trial testing Moonstone in Urinary Stone in 6 participants. Completed in 14 December 2020.

Timeline
1 September 2020
Primary endpoint
14 December 2020
14 December 2020

Quick facts

Lead sponsorNYU Langone Health
PhaseEARLY_PHASE1
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment6
Start date1 September 2020
Primary completion14 December 2020
Estimated completion14 December 2020
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

NYU Langone Health — full company profile →

Who can join

18 and older, any sex, with Urinary Stone. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will investigate the effect of a patented high citrate beverage on urine chemistry in patients with urinary stone disease (USD). It is a minimal risk study of an over-the-counter beverage called Moonstone, which is commercially available. This study is considered preparatory for the RO-1 and is not intended to produce a definitive outcome regarding kidney stones.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Urinary Stone

Currently open trials in the same condition.

Other NYU Langone Health trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04697706.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing